They are not intended to represent clinical evidence in humans, and BPC-157 has not been approved by the FDA, EMA, or any other regulatory authority for any indication
Treatment starts at 1.5 mg once daily for the first 30 days, increases to 4 mg for days 3160, then 9 mg for days 6190, before reaching the 25 mg maintenance dose on day 91
Very welcoming and professional staff
However, due to the essential nature of iron for many biological processes, chelation therapy is typically reserved for preventing iron overload in patients requiring frequent blood transfusions, such as those with sickle cell disease and thalassemia [229]
Document the dates, side effects, and lack of results for each
doi: 10.1111/hel.12881 94 WroblewskiLEChoiEPetersenCDelgadoAGPiazueloMBRomero-GalloJet al